Posted inClinical Updates Dermatology Oncology
Distinct Clinical Outcomes of Neoadjuvant PD-1 Inhibitors in Resectable Stage III Melanoma: Lymph Node Versus In-Transit Metastases
This population-based study reveals significant differences in pathological response and survival outcomes between stage III melanoma patients with lymph node metastases and those with in-transit metastases treated with neoadjuvant PD-1 inhibitors, highlighting a need for tailored therapeutic strategies.